Extended-release naltrexone versus buprenorphine-naloxone to treat opioid use disorder among black adults

被引:5
作者
Haeny, Angela M. [1 ]
Montgomery, LaTrice [2 ]
Burlew, A. Kathleen [3 ]
Campbell, Aimee N. C. [4 ,5 ]
Scodes, Jennifer [4 ,5 ]
Pavlicova, Martina [4 ,5 ]
Rotrosen, John [6 ]
Nunes, Edward [4 ,5 ]
机构
[1] Yale Sch Med, Dept Psychiat, 34 Pk St, New Haven, CT 06511 USA
[2] Univ Cincinnati, Dept Psychiat & Behav Neurosci, 3131 Harvey Ave, Cincinnati, OH 45229 USA
[3] Univ Cincinnati, Dept Psychol, 2600 Clifton Ave, Cincinnati, OH 45221 USA
[4] Columbia Univ, Dept Psychiat, Irving Med Ctr, 1051 Riverside Dr, New York, NY 10032 USA
[5] Columbia Univ, New York State Psychiat Inst, 1051 Riverside Dr, New York, NY 10032 USA
[6] NYU, Grossman Sch Med, One Pk Ave, New York, NY 10016 USA
基金
美国国家卫生研究院;
关键词
Black/African American; Opioid use disorder; Buprenorphine; Naltrexone; MULTICENTER; STANDARD; RELAPSE; DESIGN; CRISIS; TRIAL; SCALE; XBOT;
D O I
10.1016/j.addbeh.2020.106514
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Few studies examine the effectiveness of treatments for opioid use disorder (OUD) among Black individuals despite recent evidence suggesting opioid overdose death rates are, in some cases, highest and increasing at a faster rate among Black people compared to other racial/ethnic groups. This secondary analysis study investigated treatment preference, retention, and relapse rates amongst a subgroup of 73 Black participants with OUD (81% male, mean age 39.05, SD = 11.80) participating in a 24-week multisite randomized clinical trial ("X:BOT") comparing the effectiveness of extended-release naltrexone (XR-NTX) and sublingual buprenorphine-naloxone (BUP-NX) between 2014 and 2017. Chi-square analyses were used to investigate treatment preference assessed at baseline, and logistic regression analyses were used to investigate differences in the odds of retention and relapse assessed over the 24-week course of treatment between treatment groups. Our findings suggest no differences in preference for XR-NTX versus BUP-NX. However, similar to the parent trial, there was an induction hurdle such that only 59.5% of those randomized to XR-NTX successfully initiated medication compared to 91.6% of those randomized to BUP-NX (OR = 0.13, 95% CI = 0.04, 0.52). No significant differences were found in treatment retention (intention-to-treat: OR = 1.19, 95% CI = 0.43, 3.28; per-protocol [i.e., those who initiated medication]: OR = 0.60, 95% CI = 0.20, 1.82) or relapse rates between treatment groups (intention-totreat: OR = 1.53, 95% CI = 0.57, 4.13; per-protocol: OR = 0.69, 95% CI = 0.23, 2.06). Although there is a significant initiation hurdle with XR-NTX, once inducted, both medications appear similar in effectiveness, but as in the main study, dropout rates were high. Future research is needed on how to improve adherence.
引用
收藏
页数:5
相关论文
共 29 条
  • [21] Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence
    Mattick, Richard P.
    Breen, Courtney
    Kimber, Jo
    Davoli, Marina
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (03):
  • [22] Mattick RP, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002207.PUB4
  • [23] Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months
    Monico, Laura B.
    Gryczynski, Jan
    Schwartz, Robert P.
    Jaffe, Jerome H.
    O'Grady, Kevin E.
    Mitchell, Shannon Gwin
    [J]. AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2018, 44 (06) : 604 - 610
  • [24] A Systematic Scoping Review of Research on Black Participants in the National Drug Abuse Treatment Clinical Trials Network
    Montgomery, LaTrice
    Burlew, Ann Kathleen
    Haeny, Angela M.
    Jones, Chizara A.
    [J]. PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2020, 34 (01) : 117 - 127
  • [25] Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence
    Nunes, Edward V.
    Lee, Joshua D.
    Sisti, Dominic
    Segal, Andrea
    Caplan, Arthur
    Fishman, Marc
    Bailey, Genie
    Brigham, Gregory
    Novo, Patricia
    Farkas, Sarah
    Rotrosen, John
    [J]. CONTEMPORARY CLINICAL TRIALS, 2016, 51 : 34 - 43
  • [26] Psychosocial risks of prescription drug misuse among US racial/ethnic minorities: A systematic review
    Peteet, Bridgette J.
    [J]. JOURNAL OF ETHNICITY IN SUBSTANCE ABUSE, 2019, 18 (03) : 476 - 508
  • [27] Opioid Detoxification and Naltrexone Induction Strategies: Recommendations for Clinical Practice
    Sigmon, Stacey C.
    Bisaga, Adam
    Nunes, Edward V.
    O'Connor, Patrick G.
    Kosten, Thomas
    Woody, George
    [J]. AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2012, 38 (03) : 187 - 199
  • [28] SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41, DOI 10.1007/978-1-4612-0357-5_3
  • [29] Spencer M.R., NATL VITAL STAT REPO, V68